{"filings":[{"id":556485,"accession_number":"0001193125-26-232786","cik":318154,"company_name":"AMGEN INC","ticker":"AMGN","form_type":"8-K","filed_at":"2026-05-20T20:59:48+00:00","items":["5.07"],"status":"ready","headline":"Amgen annual meeting elects all 12 directors; shareholder independent-chair proposal rejected","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 12 director nominees elected; Robert Bradway received 390M votes for, 20.5M against.","Advisory vote to approve executive compensation passed with 399M for, 12M against.","Ernst & Young ratified as auditor for FY2026 with 447M for, 28M against.","Stockholder proposal to require independent board chairman failed: 72.9M for, 338.5M against.","Broker non-votes of 63.7M on all items except auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":181374356469.7051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":526797,"accession_number":"0000318154-26-000097","cik":318154,"company_name":"AMGEN INC","ticker":"AMGN","form_type":"8-K","filed_at":"2026-05-19T20:08:12+00:00","items":["5.02","9.01"],"status":"ready","headline":"Amgen CFO Peter Griffith retiring; Thomas Dittrich to succeed September 1, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Peter Griffith retiring as EVP/CFO effective Aug 31, 2026; stays as non-executive EVP through Jan 2027.","Thomas Dittrich appointed EVP/CFO effective Sep 1, 2026; returns to Amgen after CFO roles at Galderma, Shire, Sulzer.","Dittrich receives CHF 1.07M base salary, CHF 4.5M LTI target, one-time RSU of CHF 4.7M and cash bonus of CHF 4M.","Dittrich to relocate from Switzerland to Thousand Oaks; receives relocation allowance of CHF 250K and standard severance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":181374356469.7051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97950,"accession_number":"0000318154-26-000054","cik":318154,"company_name":"AMGEN INC","ticker":"AMGN","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amgen Q1 2026 revenue $8.6B (+6% YoY), Non-GAAP EPS $5.15 (+5% YoY)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $8.6B (+6% YoY); product sales grew 4% driven by 9% volume growth.","GAAP EPS $3.34 (+4% YoY); Non-GAAP EPS $5.15 (+5% YoY).","GAAP operating income $2.7B, margin 32.4% (up 17.4pp); Non-GAAP operating income $3.7B, margin 45.3% (down 0.4pp).","Free cash flow $1.5B in Q1 2026 vs $1.0B in Q1 2025.","16 products achieved double-digit sales growth in Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":3.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":8618000000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":181374356469.7051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97949,"accession_number":"0000318154-26-000048","cik":318154,"company_name":"AMGEN INC","ticker":"AMGN","form_type":"8-K","filed_at":"2026-04-22T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Amgen EVP and CTO David M. Reese to retire June 30, 2026; roles redistributed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David M. Reese retires as EVP and CTO effective June 30, 2026; responsibilities split among Bradner, Gordon, Griffith starting June 1.","James Bradner becomes EVP of R&D, AI and Data; Sean Bruich named SVP and CTO.","Murdo Gordon takes EVP of Amgen Global Markets and Policy; Paul Burton remains Chief Medical Officer.","Reese joined Amgen in 2005, led R&D from 2018-2023, and served as inaugural CTO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":181374356469.7051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":113165,"accession_number":"0001193125-26-059490","cik":318154,"company_name":"AMGEN INC","ticker":"AMGN","form_type":"8-K","filed_at":"2026-02-19T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Amgen issues $4.0B in senior notes across four tranches with maturities 2031-2056","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $1.0B 4.200% notes due 2031, $1.75B 4.850% notes due 2036, $500M 5.500% notes due 2046, $750M 5.650% notes due 2056.","Net proceeds of ~$3.96B after underwriting discounts and estimated offering expenses.","Interest payable semi-annually on Feb 19 and Aug 19, starting Aug 19, 2026.","Holders may require repurchase at 101% upon a change-in-control triggering event."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":181374356469.7051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":113164,"accession_number":"0000318154-26-000003","cik":318154,"company_name":"AMGEN INC","ticker":"AMGN","form_type":"8-K","filed_at":"2026-02-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amgen Q4 rev +9% to $9.9B; FY rev +10% to $36.8B; GAAP EPS $2.45, non-GAAP $21.84","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total revenues $9.9B (+9% YoY); product sales +7% driven by 10% volume growth.","GAAP EPS $2.45 Q4 (+111%), full year $14.23 (+88%); non-GAAP EPS full year $21.84 (+10%).","Recorded $1.2B Otezla intangible impairment due to IRA Medicare price setting.","Free cash flow $8.1B full year vs $10.4B prior, down on working capital timing.","18 products achieved record full-year sales; 14 exceeded $1B in annual sales."],"consensus_eps_estimate":null,"consensus_eps_actual":14.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":36751000000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":181374356469.7051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":113163,"accession_number":"0001193125-26-030518","cik":318154,"company_name":"AMGEN INC","ticker":"AMGN","form_type":"8-K","filed_at":"2026-01-30T23:59:59+00:00","items":["1.02","9.01"],"status":"ready","headline":"Amgen terminates rocatinlimab collaboration with Kyowa Kirin, effective upon HSR clearance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Termination agreement signed Jan 30, 2026 for 2021 License and Collaboration Agreement on rocatinlimab (KHK4083/AMG 451).","Amgen discontinuing participation; Kyowa Kirin to assume all development, manufacturing, and commercialization worldwide.","Transition effective upon satisfaction of HSR Act waiting period and other regulatory conditions.","If conditions not met by April 1, 2026 (extendable to June 1, 2026 due to government shutdown), Amgen may terminate and wind down.","Amgen and Kyowa Kirin also entering a Transition Agreement to facilitate transfer of activities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":181374356469.7051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":129560,"accession_number":"0000318154-25-000070","cik":318154,"company_name":"AMGEN INC","ticker":"AMGN","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amgen Q3 revenue up 12% to $9.6B, GAAP EPS $5.93, non-GAAP EPS $5.64","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $9.6B (+12% YoY), product sales growth 12% on 14% volume growth, partially offset by 4% lower net price.","GAAP EPS $5.93 (+14% YoY), includes $400M Otezla intangible asset impairment charge.","Non-GAAP EPS $5.64 (+1% YoY); non-GAAP operating margin 47.1%, down 2.5 ppt.","Free cash flow $4.2B vs $3.3B in Q3 2024, driven by working capital timing and lower interest.","Sixteen products delivered double-digit sales growth including Repatha, EVENITY, TEZSPIRE, and BLINCYTO."],"consensus_eps_estimate":null,"consensus_eps_actual":11.77,"consensus_revenue_estimate":null,"consensus_revenue_actual":26885000000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":181374356469.7051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":146131,"accession_number":"0000318154-25-000054","cik":318154,"company_name":"AMGEN INC","ticker":"AMGN","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amgen Q2 revenue $9.2B (+9% YoY); GAAP EPS $2.65 (+92%), non-GAAP EPS $6.02 (+21%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $9.2B, up 9% YoY; product sales up 9% on 13% volume growth, partially offset by 3% lower net selling price.","GAAP EPS $2.65 vs $1.38 (+92%); GAAP operating income $2.7B, margin 30.3%.","Non-GAAP EPS $6.02 vs $4.97 (+21%); non-GAAP operating margin 48.9%.","Free cash flow $1.9B in Q2, down from $2.2B, reflecting deferred 2024 tax payments and higher capex.","Fifteen products had double-digit sales growth, including Repatha, EVENITY, IMDELLTRA, BLINCYTO, TEZSPIRE, UPLIZNA, TAVNEOS."],"consensus_eps_estimate":null,"consensus_eps_actual":5.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":17328000000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":181374356469.7051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":164444,"accession_number":"0000950170-25-077233","cik":318154,"company_name":"AMGEN INC","ticker":"AMGN","form_type":"8-K","filed_at":"2025-05-27T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Amgen shareholders elect all 12 director nominees and approve say-on-pay at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 12 directors elected; CEO Robert A. Bradway received 375.7M for (93.0%) vs 26.4M against.","Advisory say-on-pay approved with 381.3M for (93.1%) and 21.4M against.","Ernst & Young ratified as independent auditor for FY2025 with 441.6M for (94.1%) vs 26.7M against.","Broker non-votes on director elections and say-on-pay were 64.6M shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":181374356469.7051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":164443,"accession_number":"0000318154-25-000018","cik":318154,"company_name":"AMGEN INC","ticker":"AMGN","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amgen Q1 beats: revenue $8.1B (+9%), non-GAAP EPS $4.90 (+24%), FCF $1.0B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP EPS $3.20 vs -$0.21; includes $800M Otezla intangible impairment.","Non-GAAP EPS $4.90 (+24% YoY) on revenue $8.1B (+9%).","Product sales up 11% with 14% volume growth; 14 products had double-digit growth.","Free cash flow $1.0B vs $0.5B prior year, driven by business performance.","IMDELLTRA sales $81M; Phase 3 confirmatory trial improved overall survival vs chemo."],"consensus_eps_estimate":null,"consensus_eps_actual":3.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":8149000000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":181374356469.7051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":182203,"accession_number":"0000318154-25-000005","cik":318154,"company_name":"AMGEN INC","ticker":"AMGN","form_type":"8-K","filed_at":"2025-02-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amgen Q4 revenue up 11% to $9.1B; non-GAAP EPS $5.31 (+13%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 product sales up 11% (14% volume growth); FY product sales up 19% (23% volume growth).","GAAP EPS $1.16 vs $1.42; FY $7.56 vs $12.49, driven by mark-to-market losses on equity investments.","Non-GAAP EPS $5.31 vs $4.71; FY $19.84 vs $18.65, driven by higher revenues offset by higher expenses.","Full-year free cash flow $10.4B vs $7.4B in 2023, driven by business performance and working capital timing.","21 products achieved record full-year sales; rare disease sales $1.2B in Q4."],"consensus_eps_estimate":null,"consensus_eps_actual":7.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":33424000000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":181374356469.7051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":198830,"accession_number":"0000318154-24-000042","cik":318154,"company_name":"AMGEN INC","ticker":"AMGN","form_type":"8-K","filed_at":"2024-10-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amgen Q3 2024 revenue $8.5B (+23%), GAAP EPS $5.22 (+62%), non-GAAP EPS $5.58 (+13%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $8.5B (+23% YoY); product sales grew 24% on 29% volume growth.","GAAP EPS $5.22 (+62%); non-GAAP EPS $5.58 (+13%).","Free cash flow $3.3B vs $2.5B in Q3 2023.","Rare disease portfolio contributed $1.2B in sales; 10 products had double-digit growth.","Non-GAAP operating income $4.0B; operating margin 49.6% (down 2.4 ppt)."],"consensus_eps_estimate":null,"consensus_eps_actual":6.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":24338000000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":181374356469.7051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":214871,"accession_number":"0000318154-24-000033","cik":318154,"company_name":"AMGEN INC","ticker":"AMGN","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amgen Q2 2024 revenue up 20% to $8.4B, but GAAP EPS falls 46% to $1.38","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $8.4B, up 20% YoY; product sales up 20% (5% ex-Horizon), driven by 26% volume growth.","GAAP EPS $1.38 (down 46%); non-GAAP EPS $4.97 (down 1%); GAAP operating margin 23.7% vs 40.2%.","Free cash flow $2.2B, vs $3.8B in Q2 2023, due to timing of tax payments.","Twelve products had double-digit sales growth; rare disease sales $1.1B; Repatha, Prolia, TEZSPIRE among leaders.","Non-GAAP operating income $3.9B (up 11%); operating margin 48.2%, down 4.4pp year-over-year."],"consensus_eps_estimate":null,"consensus_eps_actual":1.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":15835000000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":181374356469.7051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":234046,"accession_number":"0001193125-24-153221","cik":318154,"company_name":"AMGEN INC","ticker":"AMGN","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Amgen stockholders approve 31.3M share increase in equity plan, re-elect all 12 directors","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders approved Second Amended and Restated 2009 Equity Incentive Plan, adding 31,297,000 shares.","All 12 director nominees elected; Dr. Mary E. Klotman appointed to committees effective June 1, 2024.","Advisory vote on executive compensation passed with 93.4% of votes cast in favor.","Ernst & Young ratified as independent auditor for fiscal year 2024 with 93.7% of votes cast.","Plan amendments include clarifying dividend-equity payout timing and change-of-control vesting rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":181374356469.7051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":234045,"accession_number":"0000318154-24-000018","cik":318154,"company_name":"AMGEN INC","ticker":"AMGN","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amgen Q1 2024 revenue up 22% to $7.4B; GAAP EPS loss of $0.21 on BeiGene mark-to-market loss","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $7.4B (+22% YoY); product sales grew 22% driven by 25% volume growth; Horizon contributed $914M.","GAAP EPS loss of $0.21 vs $5.28 gain YoY, driven by mark-to-market loss on BeiGene equity investment.","Non-GAAP EPS $3.96 (-1% YoY); non-GAAP operating income $3.1B (+11% from $2.8B).","Ten products delivered double-digit volume growth including Repatha, TEZSPIRE, EVENITY, BLINCYTO, TAVNEOS.","Free cash flow $0.5B vs $0.7B; decrease from $800M tax deposit partially offset by working capital timing."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":7447000000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":181374356469.7051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":251997,"accession_number":"0000318154-24-000004","cik":318154,"company_name":"AMGEN INC","ticker":"AMGN","form_type":"8-K","filed_at":"2024-02-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amgen Q4 2023 revenue $8.2B (+20% YoY); Non-GAAP EPS $4.71 (+15% YoY)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Fourth quarter total revenue $8.2B, up 20% YoY; product sales grew 20% driven by 23% volume growth.","GAAP EPS $1.42, down 53% YoY due to acquisition-related expenses and Horizon costs.","Non-GAAP EPS $4.71, up 15% YoY; full year non-GAAP EPS $18.65, up 5%.","Horizon contributed $954M in product sales Oct 6-Dec 31; nine brands record sales in quarter.","Full year free cash flow $7.4B, down from $8.8B in 2022 due to Horizon expenses and repatriation taxes."],"consensus_eps_estimate":null,"consensus_eps_actual":12.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":28190000000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":181374356469.7051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":269534,"accession_number":"0001193125-23-295027","cik":318154,"company_name":"AMGEN INC","ticker":"AMGN","form_type":"8-K","filed_at":"2023-12-14T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Amgen names James Bradner as EVP R&D/CSO; David Reese transitions to CTO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["James Bradner, formerly President of Novartis Institutes for BioMedical Research, joins as EVP R&D and CSO effective Dec 18, 2023.","David M. Reese moves from EVP R&D to newly created EVP and Chief Technology Officer role effective Dec 18, 2023.","Both executives report to Chairman and CEO Robert A. Bradway.","Reese will lead acceleration of AI and technology across Amgen; he was key architect of Amgen's AI initiatives.","Announcement made Dec 14, 2023; appointments underscore Amgen's push to converge biotech and tech."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":181374356469.7051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":269533,"accession_number":"0000318154-23-000061","cik":318154,"company_name":"AMGEN INC","ticker":"AMGN","form_type":"8-K","filed_at":"2023-10-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amgen Q3 revenue $6.9B (+4% YoY); GAAP EPS $3.22 (-19%); Non-GAAP EPS $4.96 (+6%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $6.9B (+4% YoY); product sales +5% on 11% volume growth.","GAAP EPS $3.22 (down 19% YoY), includes ~$650M impairment for discontinued AMG 340.","Non-GAAP EPS $4.96 (+6% YoY); non-GAAP operating margin 52.0%.","Free cash flow $2.5B in Q3 vs $2.8B in prior year."],"consensus_eps_estimate":null,"consensus_eps_actual":11.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":19994000000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":181374356469.7051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":269532,"accession_number":"0001193125-23-252361","cik":318154,"company_name":"AMGEN INC","ticker":"AMGN","form_type":"8-K","filed_at":"2023-10-06T23:59:59+00:00","items":["2.01","2.03","7.01","9.01"],"status":"ready","headline":"Amgen completes $27.8B acquisition of Horizon Therapeutics at $116.50/share","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Paid $26.7B cash for Horizon shares; borrowed $4B under term loan to fund portion of consideration.","Acquisition expected to be accretive to non-GAAP EPS starting in 2024; Amgen to update FY2023 guidance on Q3 call.","Adds rare-disease drugs TEPEZZA, KRYSTEXXA, UPLIZNA to Amgen's inflammation portfolio."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":181374356469.7051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":269531,"accession_number":"0001193125-23-251090","cik":318154,"company_name":"AMGEN INC","ticker":"AMGN","form_type":"8-K","filed_at":"2023-10-05T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Amgen's acquisition of Horizon Therapeutics sanctioned by Irish High Court","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Irish High Court sanctioned the scheme of arrangement on October 5, 2023, moving deal closer to completion.","Completion remains subject to delivery of the court order to the Registrar of Companies in Ireland.","Deal originally announced December 11, 2022, valued at ~$27.8B."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":181374356469.7051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":286511,"accession_number":"0001193125-23-233011","cik":318154,"company_name":"AMGEN INC","ticker":"AMGN","form_type":"8-K","filed_at":"2023-09-12T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Amgen and Horizon extend acquisition outside date to Dec 12, 2023; Irish court hearing Oct 5","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["First Extended End Date automatically extended to Second Extended End Date, December 12, 2023.","Irish High Court set hearing for October 5, 2023 to consider sanction of scheme of arrangement.","Automatic extension was previously contemplated in the Transaction Agreement dated December 11, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":181374356469.7051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":286510,"accession_number":"0001193125-23-228161","cik":318154,"company_name":"AMGEN INC","ticker":"AMGN","form_type":"8-K","filed_at":"2023-09-05T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Amgen clears FTC hurdle for Horizon acquisition; Irish court hearing Oct 5","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["US District Court dismissed preliminary injunction motion and dissolved TRO on Sept 1, 2023.","FTC administrative lawsuit against Amgen and Horizon ended after consent order agreement.","Irish High Court set Oct 5, 2023 hearing to consider Horizon's scheme of arrangement sanction.","Acquisition of Horizon moves toward close pending Irish court approval and other conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":181374356469.7051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":286509,"accession_number":"0001193125-23-227040","cik":318154,"company_name":"AMGEN INC","ticker":"AMGN","form_type":"8-K","filed_at":"2023-09-01T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Amgen and Horizon resolve FTC lawsuit; consent order clears path to close acquisition in early Q4 2023","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Consent order agreement with FTC resolves pending administrative lawsuit related to Amgen's acquisition of Horizon.","Parties will jointly file to dismiss preliminary injunction motion and dissolve TRO in U.S. District Court for Northern District of Illinois.","Amgen gave narrow assurance it has no intention or ability to bundle Horizon's TEPEZZA or KRYSTEXXA; no impact on business.","Acquisition expected to close in early Q4 2023, pending final approvals under Irish law."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":181374356469.7051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":286508,"accession_number":"0001193125-23-203033","cik":318154,"company_name":"AMGEN INC","ticker":"AMGN","form_type":"8-K","filed_at":"2023-08-04T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Amgen appoints Matthew C. Busch as new Chief Accounting Officer effective Aug 14, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Matthew C. Busch, 49, named VP, Finance and CAO; succeeds Linda H. Louie who moves to VP, Finance.","Busch's annual base salary set at $450,000; bonus target 40% of salary; long-term equity award $500,000.","Busch has held various finance roles at Amgen since 2004, most recently VP, Finance since 2021.","No employment agreement or family relationships with other officers or directors disclosed.","Transition part of leadership development; Louie will lead corporate financial planning and analysis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":181374356469.7051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":286507,"accession_number":"0000318154-23-000049","cik":318154,"company_name":"AMGEN INC","ticker":"AMGN","form_type":"8-K","filed_at":"2023-08-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amgen Q2 2023: Revenue up 6% to $7.0B; Non-GAAP EPS rises 8% to $5.00","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues increased 6% to $7.0B; product sales volume growth of 11% partially offset by FX and price.","GAAP EPS $2.57 (up 5% YoY); Non-GAAP EPS $5.00 (up 8% YoY), driven by record revenues.","Free cash flow $3.8B vs $1.7B in Q2 2022, due to timing of tax payments and higher income.","Pipeline: positive top-line for tarlatamab in small cell lung cancer and LUMAKRAS+Vectibix in colorectal cancer.","Volume growth double-digit for EVENITY, BLINCYTO, Repatha, LUMAKRAS, Vectibix, KYPROLIS, Nplate, AMJEVITA."],"consensus_eps_estimate":null,"consensus_eps_actual":7.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":13091000000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":181374356469.7051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":306418,"accession_number":"0001193125-23-160316","cik":318154,"company_name":"AMGEN INC","ticker":"AMGN","form_type":"8-K","filed_at":"2023-06-05T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Amgen-Horizon deal TRO extended to Oct 31; FTC injunction hearing set Sept 11","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Court granted revised stipulated TRO extending the block on closing to Oct 31, 2023 or 2 business days after ruling on FTC injunction.","Evidentiary hearing on FTC's request for preliminary injunction scheduled to begin Sept 11, 2023.","If court denies FTC's injunction, Amgen expects the acquisition could close by mid-December 2023.","FTC filed complaint May 16 seeking to enjoin the acquisition; initial TRO was set to expire Sept 15."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":181374356469.7051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":306417,"accession_number":"0001193125-23-150659","cik":318154,"company_name":"AMGEN INC","ticker":"AMGN","form_type":"8-K","filed_at":"2023-05-22T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Amgen shareholders elect all 13 director nominees, approve executive compensation and auditor ratification","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 13 director nominees elected; Greg C. Garland received highest votes against at 48.8M shares.","Advisory vote to approve executive compensation passed with 371,994,642 votes for (94% of cast).","Stockholders selected one-year frequency for future advisory votes on executive compensation.","Ratification of Ernst & Young as independent auditor for FY2023 passed with 438,448,567 votes for (95% of cast)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":181374356469.7051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":306416,"accession_number":"0001193125-23-147662","cik":318154,"company_name":"AMGEN INC","ticker":"AMGN","form_type":"8-K","filed_at":"2023-05-18T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"FTC obtains stipulated TRO blocking Amgen's Horizon acquisition until Sept 15 or court ruling","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FTC filed complaint May 16, 2023 in N.D. Illinois seeking to enjoin $27.8B acquisition of Horizon Therapeutics.","Stipulated TRO granted May 17, 2023: Amgen and Horizon cannot close deal until Sept 15, 2023 or 2nd business day after court rules on FTC's preliminary injunction request.","Parties agreed to the stipulated TRO to allow court to consider the FTC's request."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":181374356469.7051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":306415,"accession_number":"0001193125-23-146219","cik":318154,"company_name":"AMGEN INC","ticker":"AMGN","form_type":"8-K","filed_at":"2023-05-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"FTC sues to block Amgen's Horizon acquisition; Amgen vows to fight","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FTC filed complaint in federal court seeking to enjoin acquisition of Horizon Therapeutics.","Amgen calls FTC's bundling theory 'entirely speculative' and says no prior deal blocked on that theory.","Amgen committed not to bundle Horizon products at issue, but FTC still proceeded with lawsuit.","Amgen intends to work with court to close transaction by mid-December."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":181374356469.7051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":306414,"accession_number":"0000318154-23-000026","cik":318154,"company_name":"AMGEN INC","ticker":"AMGN","form_type":"8-K","filed_at":"2023-04-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amgen Q1 2023: Revenue $6.1B (-2%); GAAP EPS $5.28; non-GAAP EPS $3.98 (-6%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $6.1B (-2% YoY); product sales +2% with 14% volume growth; ex-U.S. volume grew 22%.","GAAP EPS $5.28 (+97% YoY) on BeiGene mark-to-market gain; non-GAAP EPS $3.98 (-6%) driven by higher R&D.","GAAP operating income $1.9B (32.9% margin); non-GAAP operating income $2.8B (48.3% margin).","Free cash flow $0.7B vs $2.0B in Q1 2022, due to payment timing and higher capex for new facilities.","CEO reaffirms planned closing of Horizon Therapeutics acquisition."],"consensus_eps_estimate":null,"consensus_eps_actual":5.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":6105000000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":181374356469.7051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":325557,"accession_number":"0001193125-23-066144","cik":318154,"company_name":"AMGEN INC","ticker":"AMGN","form_type":"8-K","filed_at":"2023-03-09T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"Amgen terminates $28.5B Horizon bridge facility, enters new $4B revolver","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Bridge credit facility (originally $28.5B) for Horizon Therapeutics acquisition terminated March 9, 2023 after reductions from $4B term loan and $23.8B senior note proceeds.","New $4.0B revolving credit agreement signed with 5-year initial term, extendable up to two additional years, for general corporate purposes and commercial paper backstop.","Interest on revolver advances is Adjusted Term SOFR plus 0.68%-1.10% (or base rate plus 0.00%-0.10%) depending on Amgen's senior debt rating.","Company states sufficient liquidity from term loan, note proceeds, and cash to complete Horizon acquisition; remaining bridge commitments were not needed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":181374356469.7051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":325556,"accession_number":"0001193125-23-058235","cik":318154,"company_name":"AMGEN INC","ticker":"AMGN","form_type":"8-K","filed_at":"2023-03-02T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Amgen issues $24B in senior notes to fund Horizon Therapeutics acquisition","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $24B aggregate principal across eight tranches (2025-2063 maturities) with rates 5.150%-5.750%.","Net proceeds ~$23.77B after discounts and expenses; used to fund Horizon acquisition.","If Horizon acquisition not consummated by Jan 31, 2024, notes subject to special mandatory redemption at 101% plus accrued interest.","Bridge credit facility commitments reduced by net proceeds from this offering.","Notes rank senior unsecured, effectively subordinated to subsidiary obligations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":181374356469.7051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":325555,"accession_number":"0001193125-23-040753","cik":318154,"company_name":"AMGEN INC","ticker":"AMGN","form_type":"8-K","filed_at":"2023-02-16T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Amgen issues $24B of senior notes across eight tranches from 2025 to 2063","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$2B of 5.250% notes due 2025, $1.5B of 5.507% notes due 2026, $3.75B of 5.150% notes due 2028.","$2.75B of 5.250% notes due 2030, $4.25B of 5.250% notes due 2033, $2.75B of 5.600% notes due 2043.","$4.25B of 5.650% notes due 2053, $2.75B of 5.750% notes due 2063; total $24B aggregate principal.","Notes rank equal with other senior unsecured debt; closing expected March 2, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":181374356469.7051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":325554,"accession_number":"0000318154-23-000011","cik":318154,"company_name":"AMGEN INC","ticker":"AMGN","form_type":"8-K","filed_at":"2023-01-31T23:59:59+00:00","items":["1.01","2.02","8.01","9.01"],"status":"ready","headline":"Amgen posts flat Q4 revenue $6.8B, GAAP EPS down 11%; FTC extends HSR review for Horizon deal","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP EPS $3.00 (down 11% YoY); non-GAAP EPS $4.09 (down 7% YoY).","Total revenue $6.8B unchanged; product sales +4% with 10% volume growth.","Full year 2022 revenue $26.3B (+1%), GAAP EPS $12.11, non-GAAP EPS $17.69.","FTC issued Second Request for Horizon acquisition, extending HSR waiting period 30 days after compliance.","2023 guidance provided excluding Horizon; free cash flow $8.8B for full year 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":12.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":26323000000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":181374356469.7051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":343298,"accession_number":"0001193125-22-311112","cik":318154,"company_name":"AMGEN INC","ticker":"AMGN","form_type":"8-K","filed_at":"2022-12-22T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Amgen enters $4B term loan facility for Horizon acquisition, Dec 22, 2022","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Term Loan Credit Agreement provides a $2B 18-month tranche and a $2B 3-year tranche, dated Dec 22, 2022.","Facility replaces $4B of the $8B bridge credit facility entered Dec 12, 2022.","Advances bear interest at SOFR + 0.875%-1.375% or base rate plus 0.000%-0.375%; ticking fee of 0.125% on undrawn commitments.","Proceeds used to finance Horizon acquisition, repay Horizon debt, pay fees and expenses.","Commitments terminate upon completion of acquisition or mandatory cancellation events (e.g., abandonment)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":181374356469.7051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":343297,"accession_number":"0001193125-22-302256","cik":318154,"company_name":"AMGEN INC","ticker":"AMGN","form_type":"8-K","filed_at":"2022-12-12T23:59:59+00:00","items":["1.01","2.03","7.01","9.01"],"status":"ready","headline":"Amgen to acquire Horizon Therapeutics for $116.50/share; $28.5B bridge facility arranged","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Cash offer of $116.50 per Horizon share; transaction unanimously recommended by Horizon Board.","Closing expected first half of 2023, subject to Horizon shareholder, Irish court, and regulatory approvals.","Bridge credit facility of $28.5B entered to finance consideration and repay Horizon debt.","Amgen pays ~$974M termination fee under certain regulatory failure scenarios.","Conditions include antitrust clearances in US, Austria, Germany; foreign investment in France, Germany, Denmark, Italy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":181374356469.7051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":343296,"accession_number":"0001193125-22-297131","cik":318154,"company_name":"AMGEN INC","ticker":"AMGN","form_type":"8-K","filed_at":"2022-12-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Amgen confirms potential all-cash offer for Horizon Therapeutics","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Amgen states any offer for Horizon will be solely in cash.","No certainty that a formal offer will be made; further updates expected.","Disclosure follows Horizon's Rule 2.4 announcement; made under Irish Takeover Rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":181374356469.7051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":343295,"accession_number":"0000318154-22-000053","cik":318154,"company_name":"AMGEN INC","ticker":"AMGN","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amgen Q3: GAAP EPS $3.98, non-GAAP $4.70; revenue $6.7B (-1%); volumes +8%; FY22 rev guide $26.0-26.3B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP EPS $3.98 (up from $3.31); non-GAAP EPS $4.70 (up from $4.08).","Total revenues $6.7B, down 1% YoY; product sales volumes grew 8%, offset by 5% lower net price and 2% FX headwind.","Free cash flow $2.8B in Q3 versus $2.2B in prior year.","FY 2022 revenue guidance revised to $26.0-26.3B; GAAP EPS $11.46-12.17; non-GAAP EPS $17.25-17.85.","Non-GAAP policy changed: upfront license fees no longer excluded; Q3 2021 non-GAAP EPS recast downward by $0.59."],"consensus_eps_estimate":null,"consensus_eps_actual":9.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":19484000000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":181374356469.7051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":343294,"accession_number":"0001193125-22-265755","cik":318154,"company_name":"AMGEN INC","ticker":"AMGN","form_type":"8-K","filed_at":"2022-10-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Amgen completes $3.7B acquisition of ChemoCentryx, adding TAVNEOS to portfolio","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition closed at $52 per share in cash, aggregate consideration ~$3.7 billion.","Adds TAVNEOS (avacopan), a first-in-class oral therapy for severe active ANCA-associated vasculitis.","Also includes three early-stage drug candidates targeting chemoattractant receptors and an oral checkpoint for cancer.","TAVNEOS approved by FDA in Oct 2021; being studied in hidradenitis suppurativa and C3 glomerulopathy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":181374356469.7051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":359849,"accession_number":"0001193125-22-224115","cik":318154,"company_name":"AMGEN INC","ticker":"AMGN","form_type":"8-K","filed_at":"2022-08-18T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Amgen issues $3B in senior notes across three tranches with maturities 2029-2053","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $1.25B of 4.050% Senior Notes due 2029, $750M of 4.200% due 2033, and $1.0B of 4.875% due 2053.","Net proceeds approximately $2.976B after underwriters' discounts and estimated offering expenses.","Notes are senior unsecured and rank equally with other senior unsecured indebtedness of the company.","Interest payable semi-annually; first payment Feb 18, 2023 (2029 notes) and March 1, 2023 (2033 and 2053 notes).","Change-in-control triggering event allows holders to require repurchase at 101% of principal plus accrued interest."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":181374356469.7051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":359848,"accession_number":"0001193125-22-211860","cik":318154,"company_name":"AMGEN INC","ticker":"AMGN","form_type":"8-K","filed_at":"2022-08-04T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Amgen to acquire ChemoCentryx for $52/share (~$3.7B) including TAVNEOS","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Amgen will pay $52 per share in cash, enterprise value ~$3.7B; deal unanimously approved by both boards.","TAVNEOS (avacopan) is a first-in-class oral C5aR inhibitor approved Oct 2021 for ANCA-associated vasculitis; Q1 2022 US sales $5.4M.","Transaction expected to close Q4 2022, subject to ChemoCentryx stockholder approval, HSR clearance, and other conditions.","ChemoCentryx must pay Amgen a termination fee of ~$119M if it terminates for a superior proposal or under certain circumstances.","Acquisition includes early-stage pipeline: three inflammatory disease candidates and an oral checkpoint inhibitor for cancer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":181374356469.7051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":359847,"accession_number":"0000318154-22-000039","cik":318154,"company_name":"AMGEN INC","ticker":"AMGN","form_type":"8-K","filed_at":"2022-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amgen Q2 2022: GAAP EPS $2.45, revenue $6.6B; guidance updated; non-GAAP policy change","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $6.6B (+1% YoY); product sales +3% driven by Repatha, Prolia, LUMAKRAS, EVENITY.","GAAP EPS $2.45 vs $0.81 YoY; non-GAAP EPS $4.65 vs $1.77 YoY; free cash flow $1.7B flat.","2022 revenue guidance revised to $25.5-$26.4B; non-GAAP EPS reaffirmed $17-$18.","Updated non-GAAP policy excludes upfront/milestone payments; prior 2021 non-GAAP EPS recast to $13.92 from $17.10."],"consensus_eps_estimate":null,"consensus_eps_actual":5.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":12832000000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":181374356469.7051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":359846,"accession_number":"0001193125-22-211269","cik":318154,"company_name":"AMGEN INC","ticker":"AMGN","form_type":"8-K","filed_at":"2022-08-03T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Amgen appoints Michael V. Drake to Board of Directors effective August 3, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Drake is president of the University of California, with medical and academic leadership background.","Board now has 13 directors, 12 of whom are independent.","He will serve on the Corporate Responsibility & Compliance and Governance & Nominating Committees.","Standard director compensation includes pro-rated annual retainer of $105,000, committee retainer of $12,500, and RSU grant valued at $210,000.","No arrangements or transactions exist between Dr. Drake and Amgen."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":181374356469.7051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":378708,"accession_number":"0001193125-22-154061","cik":318154,"company_name":"AMGEN INC","ticker":"AMGN","form_type":"8-K","filed_at":"2022-05-18T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Amgen shareholders elect all 12 director nominees, approve say-on-pay, ratify EY auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 12 director nominees elected; highest against votes: R. Sugar (66.9M) and R. Eckert (62.8M).","Advisory vote on executive compensation passed: 357.8M for, 40.7M against, 1.9M abstain.","Ernst & Young ratified as auditor for FY2022: 436.5M for, 26.8M against, 0.7M abstain.","Broker non-votes of 63.6M shares on director elections and say-on-pay; no non-votes on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":181374356469.7051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":378707,"accession_number":"0000318154-22-000019","cik":318154,"company_name":"AMGEN INC","ticker":"AMGN","form_type":"8-K","filed_at":"2022-04-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amgen Q1 revenues up 6% to $6.2B; Non-GAAP EPS $4.25, +15%; reaffirms 2022 guide","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $6.2B (+6% YoY); product sales grew 2% with double-digit volume growth for Repatha, Prolia, EVENITY.","GAAP EPS $2.68 (-5%); Non-GAAP EPS $4.25 (+15%) on revenue growth and lower share count.","GAAP operating income $2.5B (+17%); Non-GAAP operating margin 54.8% (+3.6 ppts).","Free cash flow $2.0B vs $1.9B in Q1 2021.","2022 guidance: revenue $25.4-26.5B; GAAP EPS $12.53-13.58; Non-GAAP EPS $17-18 reaffirmed."],"consensus_eps_estimate":null,"consensus_eps_actual":2.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":6238000000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":181374356469.7051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":396963,"accession_number":"0001193125-22-052558","cik":318154,"company_name":"AMGEN INC","ticker":"AMGN","form_type":"8-K","filed_at":"2022-02-25T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Amgen enters $6B accelerated share repurchase agreements; initial delivery of ~23.3M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered ASR agreements with Bank of America, Morgan Stanley, and Goldman Sachs to repurchase up to $6B of common stock.","Initial delivery of approximately 23,258,997 shares expected on February 25, 2022.","Final settlement based on volume-weighted average price; scheduled for Q3 2022.","Funded with existing cash resources."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":181374356469.7051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":396962,"accession_number":"0001193125-22-048514","cik":318154,"company_name":"AMGEN INC","ticker":"AMGN","form_type":"8-K","filed_at":"2022-02-22T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Amgen issues $4B of senior notes across four tranches with maturities to 2062","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $750M 3.000% notes due 2029, $1B 3.350% notes due 2032, $1B 4.200% notes due 2052, $1.25B 4.400% notes due 2062.","Net proceeds of ~$3.949B after underwriters' discounts and estimated offering expenses.","Notes rank equally with other senior unsecured debt; effectively subordinated to subsidiary obligations.","Interest payable semi-annually on Feb 22 and Aug 22, beginning Aug 22, 2022.","Change-of-control trigger requires repurchase at 101% of principal plus accrued interest."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":181374356469.7051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":396961,"accession_number":"0000318154-22-000005","cik":318154,"company_name":"AMGEN INC","ticker":"AMGN","form_type":"8-K","filed_at":"2022-02-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amgen Q4 non-GAAP EPS $4.36, up 26% YoY; full-year revenue $26.0B (+2%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total revenues $6.8B (+3% YoY); product sales -1% but volumes up for Prolia, Repatha, MVASI, EVENITY.","GAAP EPS $3.36 (+22% Q4); full-year GAAP EPS $10.28 (-16%) due to $1.5B Five Prime IPR&D write-off.","Non-GAAP EPS $4.36 Q4 (+26%), full-year $17.10 (+6%); non-GAAP operating margin 51.1%.","Full-year free cash flow $8.4B, down from $9.9B due to 2020 swap monetization and capex timing.","Quarterly dividend raised to $1.76/share, up 10% YoY (full-year $7.04, +10%)."],"consensus_eps_estimate":null,"consensus_eps_actual":10.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":25979000000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":181374356469.7051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":396960,"accession_number":"0001193125-22-023401","cik":318154,"company_name":"AMGEN INC","ticker":"AMGN","form_type":"8-K","filed_at":"2022-01-31T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"Amgen amends Aimovig collaboration with Novartis, ends US royalties and cost-sharing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Novartis gets sole commercialization rights for Aimovig outside US and Japan; Amgen ends royalty payments on US sales.","U.S. Collaboration Agreement terminated Jan 31, 2022; parties no longer share US commercialization costs.","Amgen's share of Franchise Product 1 (Aimovig) development costs capped at $[***] aggregate; thereafter split 50/50.","Litigation between the parties resolved concurrently with these amendments.","Novartis to fund US Medical Affairs activities until a defined completion date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":181374356469.7051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-01-31T23:59:59+00:00|396960"}